Form 4: Acurx Pharmaceuticals CFO Granted Stock Options

Robert G. Shawah, CFO of Acurx Pharmaceuticals, was granted stock options to purchase 145,500 shares of the company's common stock on February 5, 2025.

Summary

• Robert G. Shawah, the Chief Financial Officer of Acurx Pharmaceuticals, Inc., was granted stock options on February 5, 2025.
• The stock options allow Shawah to purchase 145,500 shares of Acurx's common stock at an exercise price of $0.7982 per share.
• The options vest immediately and expire on February 5, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance. The immediate vesting is a positive sign for the executive.

Positives

• The immediate vesting of the options could incentivize the CFO to contribute to the company's success.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice in the pharmaceutical industry to incentivize executives.
• The size of the grant (145,500 shares) would need to be compared to grants given to CFOs at similarly sized pharmaceutical companies to determine if it is above or below industry averages.
• Companies like BioCryst Pharmaceuticals and Paratek Pharmaceuticals also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Acurx Pharmaceuticals, CFO, Robert G. Shawah, ACXP, equity compensation